Diary - News
All news Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement
Saint-Herblain, France, and Vienna, Austria, December 06, 2018 – Valneva Sweden AB, the Swedish subsidiary of Valneva SE (“Valneva”), and HOOKIPA Pharma Inc. (“HOOKIPA”) today announced that they have entered into a three-year collaboration and manufacturing agreement.
Under the terms of the agreement, Valneva Sweden will provide analytical services, develop process scale-up and produce GMP clinical trial material to support the development of new immunotherapies based on HOOKIPA’s Vaxwave®*and TheraT®*arenavirus vector- technologies. In return, Valneva will receive fixed and success-based service fees. The agreement may be extended beyond three years.
